Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

789.55INR
18 Apr 2019
Change (% chg)

Rs7.15 (+0.91%)
Prev Close
Rs782.40
Open
Rs785.00
Day's High
Rs794.00
Day's Low
Rs779.00
Volume
1,602,160
Avg. Vol
2,319,101
52-wk High
Rs830.45
52-wk Low
Rs527.00

Latest Key Developments (Source: Significant Developments)

Health Canada Says Auro Pharma Voluntarily Recalls One Lot Of Auro-Irbesartan HCT Tablets Because Of Nitrosamine Impurity
Friday, 19 Apr 2019 

April 18 (Reuters) - Aurobindo Pharma Ltd ::HEALTH CANADA - AURO PHARMA INC VOLUNTARILY RECALLS ONE LOT OF AURO-IRBESARTAN HCT TABLETS BECAUSE OF NITROSAMINE IMPURITY.  Full Article

Aurobindo Pharma's U.S. Unit Recalled Some Amlodipine Valsartan Tablets, Valsartan Hctz Tablets, Valsartan Tablets On Dec 31
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Aurobindo Pharma Ltd ::US UNIT INITIATED VOLUNTARY RECALL OF 80 LOTS OF AMLODIPINE VALSARTAN TABLETS , VALSARTAN HCTZ TABLETS, VALSARTAN TABLETS ON DEC 31.SAYS VALUE OF PRODUCTS BEING RECALLED IS NOT MATERIAL .  Full Article

Aurobindo Pharma Gets U.S. FDA Approval For Vecuronium Bromide Injection
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Aurobindo Pharma Ltd ::GETS USFDA APPROVAL FOR VECURONIUM BROMIDE INJECTION.PRODUCT WILL BE LAUNCHED IN Q4FY19.  Full Article

India's Aurobindo Pharma Gets U.S FDA Approval For Potassium Chloride ER Tablets
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aurobindo Pharma Ltd ::GETS U.S FDA APPROVAL FOR POTASSIUM CHLORIDE ER TABLETS.SAYS POTASSIUM CHLORIDE TABLETS ARE INDICATED FOR THE TREATMENT OF HYPOKALEMIA.PRODUCT WILL BE LAUNCHED IN JANUARY 2019.  Full Article

Aurobindo Pharma Says Co Not Yet Served With Legal Notice W.R.T. U.S. Suit Over Impurities
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Aurobindo Pharma Ltd ::AUROBINDO PHARMA CLARIFIES ON NEWS REPORT ON CO FACING U.S. SUIT OVER IMPURITIES.HAVE NOT YET BEEN SERVED WITH LEGAL NOTICE.  Full Article

European Medicines Agency Says EU Authorities Placing Zheijiang Huahai Under Increased Supervision
Monday, 15 Oct 2018 

Oct 15 (Reuters) - European Medicines Agency::EUROPEAN MEDICINES AGENCY - EU AUTHORITIES ARE PLACING THE CHINESE COMPANY ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION.EMA SAYS INSPECTION FINDINGS INCLUDED DEFICIENCIES IN THE WAY ZHEIJIANG HUAHAI INVESTIGATED IMPURITIES IN ITS VALSARTAN PRODUCTS.EUROPEAN MEDICINES AGENCY SAYS AUROBINDO PHARMA STOPPED FROM SUPPLYING IRBESARTAN TO THE EU.EMA SAYS AUTHORITIES IN EU CURRENTLY CONSIDERING WHETHER TO RECALL MEDICINES CONTAINING AUROBINDO PHARMA’S IRBESARTAN FROM PHARMACIES AS A PRECAUTION.EMA SAYS MARKETING AUTHORISATION HOLDERS FOR EU MEDICINES TO BE REQUIRED TO PERFORM MORE TESTS ON ALL ACTIVE SUBSTANCES SUPPLIED BY ZHEJIANG HUAHAI.EMA- PLACING ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION AFTER INSPECTIONS SHOWED WEAKNESSES IN QUALITY MANAGEMENT AT ITS CHUANNAN SITE IN LINHAI.  Full Article

Aurobindo Pharma Gets Approval From South African Regulator For Certain Tablets
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Aurobindo Pharma Ltd ::AUROBINDO PHARMA -APPROVAL FROM SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY FOR DOLUTEGRAVIR, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE TABLETS.  Full Article

Novartis AG Says Faces Impairment Of About Usd70 Million Related To Sale Of Assets To India's Aurobindo, Will Confirm At Q3 Earnings Report On Oct 18
Thursday, 6 Sep 2018 

Novartis Ag ::SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.  Full Article

Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Aurobindo Pharma Ltd ::UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA.DEAL FOR $0.9 BILLION IN CASH ON DEBT FREE AND CASH FREE BASIS INCLUDING POTENTIAL UPSIDE IN NEAR TERM EARN-OUT.DEAL WILL BE AN ALL CASH TRANSACTION WHICH AUROBINDO WILL FINANCE THROUGH A FULLY COMMITTED DEBT FACILITY.  Full Article

India's Aurobindo Pharma March Quarter Consol Profit Slips
Monday, 28 May 2018 

May 28 (Reuters) - Aurobindo Pharma Ltd ::MARCH QUARTER CONSOL NET PROFIT 5.29 BILLION RUPEES VERSUS 5.32 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL NET PROFIT WAS 5.98 BILLION RUPEES.MARCH QUARTER CONSOL INCOME FROM OPERATIONS 39.89 BILLION RUPEES VERSUS 35.82 BILLION RUPEES LAST YEAR.  Full Article

MEDIA-India's Aurobindo Pharma’s Unit IV on U.S FDA radar - Times Of India

- Note: Reuters has not verified this story and does not vouch for its accuracy